Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5382 - Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Prostate Cancer

Presenters

Christoph Reuter

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

C.W.M. Reuter1, S. Brunotte1, P. Ivanyi1, M.A. Morgan2, V. Grünwald3

Author affiliations

  • 1 Hematology, Hemostaseology, Oncology And Stell Cell Transplantation, Hannover Medical School, 30625 - Hannover/DE
  • 2 Exp. Hematology, Hannover Medical School, 30625 - Hannover/DE
  • 3 Hematology, Hemostaseology, Oncology And Stem Cell Transplantation, Medical School Hannover, 30625 - Hannover/DE
More

Resources

Abstract 5382

Background

Recent data suggest that carboplatin plus weekly docetaxel (DC) may be effective in mDRPC. Platinum(II)-complexes have been shown to interfere with steroid biosynthesis lowering testosterone levels by inhibiting the cholesterol side chain cleavage enzyme (CYP11A1), 3β-hydroxysteroid dehydrogenase (HSD3B1,2) and 17α hydroxylase/C17,20-lyase (CYP17A1).

Methods

Docetaxel failure/resistance was defined according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Treatment consisted of at least two cycles of carboplatin AUC5 iv for 30 min on day 1 every 4 weeks (q4w), docetaxel at a dose of 35 mg/m2 iv for one hour on days 1, 8, (15) plus prednisone 2x5mg/day orally after receiving informed consent until disease progression or occurrence of intolerable adverse effects. Efficacy measures were done following PCWG2 recommendations. Free testosterone levels were measured before (n = 82) and during carboplatin/docetaxel chemotherapy (n = 76).

Results

Of the 106 pts. treated since February 2005, 96.2% had bone and 63.2 % soft tissue metastases ( 45% lymph node, 27% liver and 21% lung involvement). At the time of the current analysis, the median follow-up time was 13.5 months, 101 pts. had died and 102 had progressive disease. The objective response rate was 43.2% and the disease control rate 64.2% in the 67 pts. with measureable disease. Response of prostate-specific antigen (≥50%) was observed in 50 patients (47.1%). Median progression-free survival (PFS) for all patients was 6.9 months (CI 95% 5.7, 8.0) and median OS was 14.1 months (CI 95% 10.9, 17.3). The most common reversible grade 3/4 toxicity was leukopenia/ neutropenia (40.5/32.1%). Median free and total testosterone levels were reduced below the detection limit during DC treatment (from 0.55 pg/ml to < 0.18 pg/ml and 0.08 to < 0.05 ng/ml, respectively). Testosterone nadir values <0.18 pg/ml during DC treatment were associated with longer PFS, OS and post-hoc OS (p < 0.05).

Conclusions

These data suggest that carboplatin plus weekly docetaxel may be an important second-line treatment option for DRPC patients by inhibition the testosterone biosynthesis.

Clinical trial identification

Legal entity responsible for the study

Christoph Reuter.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

C.W.M. Reuter: Advisory board: Eisai, Bayer, Tesaro, Sanofi, Astellas, Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.